Genocea Biosciences Inc (NASDAQ:GNCA)’s share price rose 8.3% during trading on Friday . The stock traded as high as $2.69 and last traded at $2.62, approximately 169,727 shares traded hands during mid-day trading. A decline of 47% from the average daily volume of 320,502 shares. The stock had previously closed at $2.42.

GNCA has been the subject of several research reports. Stifel Nicolaus initiated coverage on Genocea Biosciences in a research report on Monday, July 8th. They issued a “buy” rating for the company. HC Wainwright set a $32.00 target price on Genocea Biosciences and gave the company a “buy” rating in a research report on Monday, September 30th. ValuEngine upgraded Genocea Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, September 25th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Genocea Biosciences in a research report on Monday, September 30th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $17.50.

The company has a debt-to-equity ratio of 0.45, a current ratio of 5.96 and a quick ratio of 5.96. The company has a market capitalization of $63.28 million, a P/E ratio of -0.71 and a beta of 2.45. The stock has a 50-day moving average price of $3.17 and a 200-day moving average price of $2.85.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, July 25th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.02). Sell-side analysts anticipate that Genocea Biosciences Inc will post -2.13 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of GNCA. FNY Investment Advisers LLC bought a new position in shares of Genocea Biosciences during the second quarter worth about $526,000. Monashee Investment Management LLC bought a new position in shares of Genocea Biosciences during the second quarter worth about $392,000. DRW Securities LLC bought a new position in shares of Genocea Biosciences during the second quarter worth about $118,000. Wells Fargo & Company MN raised its position in shares of Genocea Biosciences by 271.9% during the second quarter. Wells Fargo & Company MN now owns 33,631 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 24,587 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. bought a new position in shares of Genocea Biosciences during the second quarter worth about $84,000. Institutional investors own 55.91% of the company’s stock.

About Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Further Reading: Rule of 72

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.